FY2025 Earnings Forecast for Amarin Issued By Zacks Research

Amarin Corporation PLC (NASDAQ:AMRN) – Zacks Research reduced their FY2025 earnings estimates for shares of Amarin in a note issued to investors on Monday, December 22nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($2.03) per share for the year, down from their prior forecast of ($1.97). Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2026 earnings at ($1.69) EPS, FY2026 earnings at ($3.86) EPS, Q2 2027 earnings at ($0.03) EPS and FY2027 earnings at ($3.41) EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research note on Wednesday, October 8th. Wall Street Zen cut Amarin from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Sell” and a consensus price target of $12.00.

Amarin Price Performance

Shares of Amarin stock opened at $13.66 on Wednesday. The business has a 50-day simple moving average of $16.32 and a 200 day simple moving average of $15.85. Amarin has a one year low of $7.08 and a one year high of $20.90. The firm has a market capitalization of $283.99 million, a price-to-earnings ratio of -5.49 and a beta of 0.71.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Two Sigma Investments LP boosted its position in shares of Amarin by 1.8% during the third quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 1,047 shares during the last quarter. Sei Investments Co. raised its position in Amarin by 4.7% in the 3rd quarter. Sei Investments Co. now owns 29,212 shares of the biopharmaceutical company’s stock valued at $478,000 after buying an additional 1,299 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in Amarin during the 3rd quarter valued at $32,000. GPS Wealth Strategies Group LLC bought a new position in Amarin during the 2nd quarter valued at $32,000. Finally, Ameriprise Financial Inc. boosted its holdings in Amarin by 13.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 2,008 shares during the last quarter. Institutional investors own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.